Millions of Americans can now look forward to a better time traveling, with the US Food and Drug Administration (FDA) ...
Vanda Pharmaceuticals said on Tuesday its drug for the prevention of motion-induced vomiting was approved by the U.S. health ...
The FDA approved Vanda’s drug Nereus to prevent motion-induced vomiting, opening a potential path into treating nausea linked ...
Jefferies analysts envision a steady launch curve that could ultimately drive meaningful sales from people who are ...
Stocktwits on MSN
VNDA stock on track to open at three-year high – FDA clears first new motion sickness drug in decades
Two Phase 3 real-world trials, conducted on boats, showed that NEREUS significantly reduced vomiting compared with placebo.
MedPage Today on MSN
FDA Greenlights First Motion Sickness Drug in More Than 40 Years
The scopolamine skin patch (Transderm Scōp), approved in 1979, was the last drug sanctioned by the FDA to prevent motion ...
FDA approval of Vanda’s Nereus marks a rare and meaningful regulatory milestone, introducing the first new pharmacologic ...
Vanda also sells sleep disorder drug Hetlioz, which reached the market in 2014, and relapsing multiple sclerosis treatment ...
Vanda Pharmaceuticals has received FDA approval for Nereus (tradipitant), an oral NK-1 receptor antagonist developed to prevent motion-induced vomiting. The approval makes Nereus the first new ...
The FDA has approved tradipitant (Nereus), an oral NK-1 receptor antagonist, for preventing motion-induced vomiting in adults ...
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares are trading higher Wednesday after the company announced it received FDA ...
Vanda stock jumps after FDA approves tradipitant as Nereus for motion sickness, marking the first new therapy in over 40 years and boosting investor optimism.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback